• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

dgmurphy@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
Education
Bachelors Degree
National University of Ireland
ORCID

0000-0002-7500-5899

Prof Declan Murphy

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

810 Scholarly works
9 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma
    DOI: 10.1038/s41467-026-74255-x
  • 2026

    Journal article

    Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era
    DOI: 10.1002/pros.70231
  • 2026

    Research grants (ARC, NHMRC, MRFF)

    Unraveling Metastasis-Specific Immune Niches to Transform Cancer Treatment
  • 2019

    Research Grant

    Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
  • 2018

    Journal article

    Cold kit for prostate-Specific membrane antigen (PSMA) PET imaging: Phase 1 study of 68Ga-Tris (Hydroxypyridinone)-PSMA PET/CT in patients with prostate cancer
    DOI: 10.2967/jnumed.117.199554
  • 2017

    Conference Proceedings

    Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
    DOI: 10.1093/annonc/mdx370.002
  • 2017

    Research Grant

    Biofocussed Prostate Cancer Radiotherapy (Birt): A Personalised Approach to Delivering the Right Dose to the Right Place
Declan Murphy

Latest Honours,
Awards and Fellowships


2014
Fellow of the Royal Australasian College of Surgeons (FRACS)
2014
FRCS Urol The Royal College of Surgeons in Ireland - Urology

RECENT SCHOLARLY WORKS

  • 2026

    Conference Proceedings

    DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis
    DOI: 10.1038/s41391-025-01047-7
  • 2026

    Journal article

    Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer
    DOI: 10.1111/bju.70283
  • 2026

    Journal article

    Effect of the November 2023 Medicare Benefits Schedule PSA Testing Reform on National Utilisation, Diagnostic Activity, and Health-System Expenditure in Australia
    DOI: 10.3390/siuj7040058
  • 2026

    Journal article

    Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer
    DOI: 10.1001/jamanetworkopen.2026.29936
  • 2026

    Journal article

    First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT
    DOI: 10.2967/jnumed.125.271995
  • 2026

    Journal article

    Guideline of guidelines: pelvic lymph node dissection at time of radical prostatectomy
    DOI: 10.1111/bju.70277
  • 2026

    Journal article

    Long-term trends in androgen-directed therapy in advanced prostate cancer: a 29-year national analysis
    DOI: 10.1007/s11255-026-05003-9
  • 2026

    Journal article

    End of the TRUS era: transperineal biopsy takes the lead in prostate cancer detection
    DOI: 10.1038/s41585-025-01090-y

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224